SUBVENITE Drug Patent Profile
✉ Email this page to a colleague
When do Subvenite patents expire, and what generic alternatives are available?
Subvenite is a drug marketed by Owp Pharms and is included in one NDA. There are four patents protecting this drug.
The generic ingredient in SUBVENITE is lamotrigine. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Subvenite
A generic version of SUBVENITE was approved as lamotrigine by DR REDDYS LABS LTD on January 22nd, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SUBVENITE?
- What are the global sales for SUBVENITE?
- What is Average Wholesale Price for SUBVENITE?
Summary for SUBVENITE
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 4,884 |
| Drug Prices: | Drug price information for SUBVENITE |
| What excipients (inactive ingredients) are in SUBVENITE? | SUBVENITE excipients list |
| DailyMed Link: | SUBVENITE at DailyMed |
Pharmacology for SUBVENITE
| Drug Class | Anti-epileptic Agent Mood Stabilizer |
| Mechanism of Action | Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for SUBVENITE
SUBVENITE is protected by ten US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | 11,596,634 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | 12,629,377 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | 11,612,566 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | 12,636,289 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
